Skip to main content
Clinical Trials/JPRN-UMIN000039182
JPRN-UMIN000039182
Recruiting
未知

Multicenter prospective observational study to evaluate immune cell dynamics of EGFR tyrosine kinase inhibitor re-administration after administration of immune checkpoint inhibitor in patients with relapsed / advanced non-small cell lung cancer with EGFR gene mutation - A multicenter prospective observational study to evaluate immune cell dynamics of EGFR-TKI re-administration after ICI

Hamamatsu University School of Medicine0 sites40 target enrollmentJanuary 17, 2020

Overview

Phase
未知
Intervention
Not specified
Conditions
relapsed / advanced non-small cell lung cancer with EGFR gene mutation
Sponsor
Hamamatsu University School of Medicine
Enrollment
40
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 17, 2020
End Date
December 31, 2028
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • 1\) Patients with interstitial lung disease or a history of it. 2\) HBs antigen positive. 3\) HBs antibody or HBc antibody positive and HBV\-DNA positive. 4\) HCV carrier. 5\) Serious complications. 6\) A history of severe hypersensitivity. 7\) The principal investigator or the research coordinator determined that participation in this study was inappropriate.

Outcomes

Primary Outcomes

Not specified

Similar Trials